

Electrochemical NaI-mediated one-pot synthesis of guanidines from isothiocyanates *via* tandem addition-guanylation

Thao Nguyen Thanh Huynh^a, Khuyen Thu Nguyen^a, Mongkol Sukwattanasinitt^a, and Sumrit Wacharasindhu^{*a,b}

^a Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand 10330


^b Green Chemistry for Fine Chemical Productions and Environmental Remediation Research Unit, Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330

sumrit.w@chula.ac.th

Electronic Supplementary Information

Table of Contents

Title page	S1
Table S1 and Faradaic calculation	S2
General procedure	S3 – S22
Picture of experiment set up: Figure S1-S3	S23
Copy of ¹ H/ ¹³ C NMR spectrum: Figure S4-S72	S24 – S58
Copy of mass spectrum: Figure S70-S84	S59 – S70
GC-MS result of compound 5ab : Figure S85	S71
Cyclic voltammogram	S71
References	S71

Table S1. Additive screening

Entry	Additive	Yield(%) ^b
1	NaCl	40
2	LiClO ₄	58
3	TBABF ₄	29
4	NaOH	63
5	K ₂ CO ₃	62
6	Cs ₂ CO ₃	42
7	Et ₃ N	50
8	DBU	61
9	DIPEA	69

Reaction conditions: **1aa** (0.5 mmol, 1.0 eq.), **2b** (0.75 mmol, 1.5 eq.), NaI (0.5 mmol, 1.0 eq.), additive (0.5 mmol, 1.0 eq.), graphite rod (ϕ 5 mm, 20 mm immersion depth) as both cathode and anode, constant current 15 mA (4.5 F/mol), EtOH 2.5 mL, water 2.5 mL, room temperature, 4 hrs., undivided cell.

Faradaic efficiency calculation for the model substrate **4aab**:

$$\text{Faradaic efficiency} = \frac{Q_{\text{experimental}}}{Q_{\text{theoretical}}} \times 100$$

$$\text{Faradaic efficiency} = \frac{z \times n \times F}{Q_{\text{theoretical}}} \times 100$$

With z = number of electron that the reaction used = 2

$$n = \text{mol of product that obtained} = 0.5 \times 80\% = 0.4 \text{ mmol}$$

$$F = \text{Faradaic constant (96485 C/mol)}$$

$Q_{\text{theoretical}}$ can be calculated from I (current, Ampere) \times t (reaction time, second)

$$\text{Faradaic efficiency} = \frac{2 \times 0.4 \times 10^{-3} \times 96485}{0.015 \times 7200} \times 100$$

$$\text{Faradaic efficiency} = 72 \%$$

Experimental Section

Materials and methods

All chemicals and solvents were obtained from commercially available suppliers such as Sigma-Aldrich and TCI (Japan) and were used without further purification, unless otherwise stated. Pyrex reactor ($\phi = 2.0$ cm, Height = 6.2 cm) was used for electrochemical reaction. Power supply (KORAD, KA3005D) was purchased from Shenzhen Korad Technology CO., LTD. All electrodes such as graphite rod ($\phi = 5$ mm) and platinum plate (5x5x0.1 mm) were purchased from Minihua Store, China. Electrochemical reaction setup was depicted in Figures S1-S3. Analytical thin layer chromatography (TLC) was performed with precoated Merck silica gel 60 F254 plates (0.25 mm for thick layer) and visualized at 254 nm using an ultraviolet lamp. Column chromatography was performed with Silicycle silica gel 60-200 μm (70-230 mesh). $^1\text{H-NMR}$, $^{13}\text{C-NMR}$ spectra were obtained with JEOL JNM-ECZ500R/S1 NMR spectrometers operating at 500 MHz for ^1H or 125 MHz for ^{13}C nuclei or 470 MHz for ^{19}F nuclei. Melting points are measured with Barnstead international mel-temp melting point apparatus model 1201D. High-resolution mass spectra (HRMS) were recorded using electron spray ionization (ESI) with a MicroTOF Bruker mass spectrometer.


General procedure for synthesis of guanidine from thiourea (General Procedure A)

A mixture of thiourea **1** (1.0 eq., 0.5 mmol), amines **2** (3.0 eq., 1.5 mmol), sodium iodide (1.0 eq., 0.5 mmol), and DIPEA (1.0 eq., 0.5 mmol) were dissolved in mixed 2.5 mL of water with 2.5 mL of ethanol in a Pyrex reactor ($\phi = 2.0$ cm, height = 6.2 cm). The reaction mixture was electrolysed at a constant current of 15 mA (4.5 F/mol), graphite rods as both cathode and anode ($\phi = 20$ mm, about 20 mm immersion depth in solution) at room temperature for 4 hours. After the reaction, the crude mixture was extracted with water and ethyl acetate. The organic layer was evaporated under reduced pressure to give the crude product, which was further

purified by column chromatography (eluted with ethyl acetate/hexane) to afford the desired compound.

General procedure for synthesis of guanidine from amines and isothiocyanate (General Procedure B)


A mixture of amines **2** (1.0 eq., 0.5 mmol), isothiocyanates **3** (1.0 eq., 0.5 mmol), were dissolved in 2.5 mL of ethanol in a Pyrex reactor ($\phi = 2.0$ cm, height = 6.2 cm) and was allowed to stir without electricity for 1 hours at room temperature. After that, sodium iodide (1.0 eq., 0.5 mmol) in 2.5 mL of water, DIPEA (1.0 eq., 0.5 mmol), and amines **2** (3.0 eq., 1.5 mmol) were added to the solution. The reaction mixture was electrolysed at a constant current of 15 mA (4.5 F/mol), graphite rods as both cathode and anode ($\phi = 20$ mm, about 20 mm immersion depth in solution) at room temperature for 4 hours. After the reaction, the crude mixture was extracted with water and ethyl acetate. The organic layer was evaporated under reduced pressure to give the crude product, which was further purified by column chromatography (eluted with ethyl acetate/hexane) to afford the desired compound.



N,N'-diphenylmorpholine-4-carboximidamide (**4aab**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aab** (108.1 mg, 0.385 mmol, 77%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aab** (112.2 mg, 0.4 mmol, 80%) as a yellow solid: $^1\text{H NMR}$ (500 MHz, CDCl_3)


δ ppm 7.25 (t, $J = 7.8$ Hz, 4H), 7.0-6.94 (m, 6H), 3.68 (t, $J = 4.8$ Hz, 4H), 3.34 (t, $J = 4.8$ Hz, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 151.0, 129.5, 122.7, 66.5, 47.1. Melting point: 133-134°C. Data is consistent with reported literatures.¹⁻³

For gram-scale synthesis: A mixture of aniline **2a** (1.0 eq., 466.0 mg, 5.0 mmol), phenyl isothiocyanate **3a** (1.0 eq., 675 mg, 5.0 mmol), was dissolved in 25 mL of ethanol and stir at room temperature for 2 hours in a 100 mL three-necked round bottom flask. After that, sodium iodide (1.0 eq., 749.5 mg, 5.0 mmol) in 25 mL of water, DIPEA (1.0 eq., 646.0 mg, 5.0 mmol), and morpholine **2b** (3.0 eq., 1.307 g, 15 mmol) were added in the flask. The reaction mixture was then electrolysed at a constant current of 30 mA (4.5 F/mol), graphite rods as both cathode and anode at room temperature for 20 hours. The reaction was extracted with water and ethyl acetate. The organic layer was evaporated under reduced pressure to give the crude product, which was further purified by column chromatography in ethyl acetate/hexane to afford the desired compound (1.0011 g, 3.55 mmol, 71%).




1-butyl-2,3-diphenylguanidine (**4aac**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), *n*-butylamine **2c** (109.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aac** (65.2 mg, 0.245 mmol, 49%) as a brown solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), *n*-butylamine **2c** (109.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aac** (71.9 mg, 0.27 mmol, 54%) as a light brown solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.31-7.28 (m, 4H), 7.05-7.02 (m, 6H), 3.31 (t, $J = 7.3$ Hz, 2H), 1.57-1.51 (m, 2H), 1.4-1.32 (m, 2H), 0.94 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 148.6, 138.3, 129.5,

123.2, 123.1, 41.7, 31.8, 20.3, 14.0. Melting point: 68-69°C. Data is consistent with reported literatures.¹⁻³




1-cyclohexyl-2,3-diphenylguanidine (**4aad**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), cyclohexylamine **2d** (144.8 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aad** (92.1 mg, 0.315 mmol, 63%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), cyclohexylamine **2d** (144.8 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aad** (127.5 mg, 0.435 mmol, 87%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.29 (t, *J* = 7.9 Hz, 4H), 7.03 (d, *J* = 7.9 Hz, 2H), 3.76 (b, 1H), 2.09 (d, *J* = 9.5 Hz, 2H), 1.71-1.67 (m, 2H), 1.62-1.58 (m, 1H), 1.43-1.34 (m, 2H), 1.2-1.09 (m, 3H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 147.5, 129.5, 129.2, 123.0, 49.9, 33.5, 25.8, 25.0. Melting point: 141-142°C. Data is consistent with reported literatures.¹⁻³




1-benzyl-2,3-diphenylguanidine (**4aae**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), benzylamine **2e** (160.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aae** (90.1 mg, 0.3 mmol, 60%) as a yellow solid;


Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), benzylamine **2e** (160.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aae** (132.5 mg, 0.44 mmol, 88%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.39-7.36 (m, 4H), 7.33-7.3 (m, 5H), 7.09-7.04 (m, 6H), 4.56 (s, 2H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 148.3, 139.1 129.6, 128.7, 127.8, 127.4, 123.2, 45.9. Melting point: 98-99°C. Data is consistent with reported literatures.^{1,2}



1-(4-methoxybenzyl)-2,3-diphenylguanidine (**4aaf**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), 4-methoxybenzylamine **2f** (205.8 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aaf** (88.4 mg, 0.265 mmol, 53%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), 4-methoxybenzylamine **2f** (205.8 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aaf** (160.3 mg, 0.485 mmol, 97%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.31-7.28 (m, 6H), 7.06-7.02 (m, 6H), 6.89-6.87 (m, 2H), 4.47 (s, 2H), 3.81 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 159.0, 148.3, 131.2, 129.6, 129.2, 123.2, 114.1, 55.4, 45.5. Melting point: 115-116°C. Data is consistent with reported literatures.²




1-(4-fluorobenzyl)-2,3-diphenylguanidine (**4aag**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), 4-fluorobenzylamine **2g** (188.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aag** (110.9 mg, 0.35 mmol, 70%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), 4-fluorobenzylamine **2g** (188.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aag** (132.8 mg, 0.415 mmol, 83%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.37-7.31 (m, 6H), 7.09-7.03 (m, 8H), 4.53 (s, 2H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 163.2, 161.2, 154.0, 148.2, 135.1, 129.7, 129.5 (d, $J = 7.5$ Hz), 116.3, 115.5, 45.2. ESI-MS: m/z : 320.15706 $[\text{M}+\text{H}]^+$ (calcd for $[\text{C}_{20}\text{H}_{19}\text{FN}_3]^+$ 320.15630).




1-(4-chlorobenzyl)-2,3-diphenylguanidine (**4aah**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), 4-chlorobenzylamine **2h** (212.4 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aah** (107.1 mg, 0.32 mmol, 64%) as a white solid; Synthesized according to the General procedure B using aniline

2a (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), 4-chlorobenzylamine **2h** (212.4 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aah** (154.2 mg, 0.46 mmol, 92%) as a white solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.31 (t, $J = 7.8$ Hz, 8H), 7.08-7.04 (m, 6H), 4.51 (s, 2H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 148.1, 137.9, 133.0, 129.6, 129.1, 128.8, 123.3, 45.1. Melting point: 117-118°C. Data is consistent with reported literatures.²




1,2,3-triphenylguanidine (**4aaa**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), aniline **2a** (139.8 mg, 1.5 mmol), sodium iodide (149.9 mg, 1.0 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aaa** (88.5 mg, 0.31 mmol, 62%) as a white solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.33 (t, $J = 7.9$ Hz, 6H), 7.23 (b, 6H), 7.07 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 145.0, 129.5, 123.3, 121.7; ^{13}C NMR (125 MHz, $\text{CD}_3\text{OD} + 0.1\%$ TFA): δ ppm 151.0, 142.6, 130.1, 124.5, 122.5. Melting point: 145-146°C. ESI-MS: m/z : 288.15092 $[\text{M}+\text{H}]^+$ (calcd for $[\text{C}_{19}\text{H}_{18}\text{N}_3]^+$ 288.15007). Data is consistent with reported literatures.³




1-(4-methoxyphenyl)-2,3-diphenylguanidine (**4aai**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg,


0.5 mmol), *p*-anisidine **2i** (184.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aai** (90.1 mg, 0.285 mmol, 57%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.32-7.28 (m, 4H), 7.22 (b, 4H), 7.14 (d, *J* = 8.7 Hz, 2H), 7.04 (t, *J* = 7.3 Hz, 2H), 6.88-6.86 (m, 2H), 3.79 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 145.8, 129.4, 123.1, 121.6, 114.8, 55.6. Data is consistent with reported literatures.^{2,3}



1,1-diethyl-2,3-diphenylguanidine (**4aal**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), diethylamine **2i** (109.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aal** (83.6 mg, 0.315 mmol, 63%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), diethylamine **2i** (109.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aal** (136.4 mg, 0.44 mmol, 88%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.22 (t, *J* = 7.7 Hz, 4H), 6.95 (t, *J* = 7.3 Hz, 2H), 6.88 (d, *J* = 7.5 Hz, 4H), 3.34 (q, *J* = 7.1 Hz, 4H), 1.17 (t, *J* = 7.1 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 150.3, 129.3, 122.0, 42.1, 13.0. Melting point: 94-95°C. Data is consistent with reported literatures.^{1,2}




N,N'-diphenylpyrrolidine-1-carboximidamide (**4aam**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), pyrrolidine **2m** (106.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aam** (74.1 mg, 0.28 mmol, 56%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), pyrrolidine **2m** (106.7 mg, 1.5 mmol), sodium iodide (149.9 mg, 1.0 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aam** (88.2 mg, 0.335 mmol, 67%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.22-7.18 (m, 4H), 7.0-6.96 (m, 6H), 3.30 (t, *J* = 6.4 Hz, 4H), 1.82-1.80 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 150.7, 141.3, 129.4, 123.9, 121.5, 48.7, 25.2. Data is consistent with reported literatures.¹⁻³




N,N'-diphenylazepane-1-carboximidamide (**4aan**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), azepane **2n** (148.8 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aan** (111.6 mg, 0.38 mmol, 76%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), azepane **2n** (148.8 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aan** (127.2 mg, 0.435 mmol, 87%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.23 (t, *J* = 7.8 Hz, 4H), 6.97 (t, *J* = 7.4 Hz, 2H), 6.96-6.86 (m, 4H), 3.48 (t, *J* =

5.8 Hz, 4H), 1.78-1.77 (m, 4H), 1.65-1.63 (m, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 150.9, 129.3, 121.9, 48.8, 28.3, 27.9. Data is consistent with reported literatures.^{1,2}




2-Methyl-*N,N'*-diphenylpiperidine-1-carboximidamide (**4aao**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), 2-methylpiperidine **2o** (148.8 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aao** (102.3 mg, 0.35 mmol, 70%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), 2-methylpiperidine **2o** (148.8 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aao** (122.6 mg, 0.42 mmol, 84%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.23 (t, $J = 7.8$ Hz, 4H), 6.95-6.91 (m, 6H), 4.14-4.12 (m, 1H), 3.71-3.68 (m, 1H), 3.05-2.99 (m, 1H), 1.75-1.69 (m, 1H), 1.66-1.60 (m, 3H), 1.56-1.50 (m, 1H), 1.45-1.42 (m, 1H), 1.21 (d, $J = 6.9$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 150.8, 129.3, 122.0, 48.8, 41.4, 29.9, 25.6, 19.1, 14.6. Data is consistent with reported literatures.^{1,2}




tert-Butyl-4-(*N,N'*-diphenylcarbamimidoyl)piperazine-1-carboxylate (**4aap**)


Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), *tert*-butyl piperazine-1-carboxylate **2p** (279.4 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4aap** (74.2 mg, 0.195 mmol, 39%) as a yellow solid; Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), *tert*-butyl piperazine-1-carboxylate **2p** (279.4 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aap** (139.4 mg, 0.365 mmol, 73%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.25 (t, *J* = 7.6 Hz, 4H), 6.99-6.92 (m, 6H), 3.42-3.40 (m, 4H), 3.32-3.30 (m, 4H), 1.46 (s, 9H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 154.9, 151.0, 129.5, 122.7, 121.6, 80.1, 46.5, 28.5. Melting point: 125-126°C. Data is consistent with reported literatures.^{1,2}




N-phenyl-*N'*-(*o*-tolyl)morpholine-4-carboximidamide (**4qab**) Synthesized according to the General procedure B using *o*-toluidine **2q** (53.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4qab** (127.8 mg, 0.435 mmol, 87%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.28-7.24 (m, 2H), 7.16 (d, *J* = 7.1 Hz, 2H), 7.0-6.95 (m, 4H), 3.70 (b, 4H), 3.35 (t, *J* = 4.3 Hz, 4H), 2.14 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 130.8, 129.4, 126.9, 122.9, 122.5, 121.0, 118.8, 66.5, 47.2, 18.0. Data is consistent with reported literatures.¹⁻³




N-phenyl-*N'*-(*p*-tolyl)morpholine-4-carboximidamide (**4rab**) Synthesized according to the General procedure B using *p*-toluidine **2r** (53.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4rab** (125.0 mg, 0.425 mmol, 85%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.25 (t, $J = 7.7$ Hz, 2H), 7.06 (d, $J = 7.9$ Hz, 2H), 6.99-6.96 (m, 5H), 3.67 (t, $J = 4.8$ Hz, 4H), 3.32 (t, $J = 4.8$ Hz, 4H), 2.29 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 151.2, 132.1, 130.0, 129.4, 122.5, 118.7, 66.5, 47.0, 20.8. Data is consistent with reported literatures.¹⁻³



N'-(4-methoxyphenyl)-*N*-phenylmorpholine-4-carboximidamide (**4iab**) Synthesized according to the General procedure B using *p*-anisidine **2i** (61.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4iab** (143.3 mg, 0.46 mmol, 92%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.26 (t, $J = 7.9$ Hz, 2H), 6.99-6.85 (m, 5H), 6.8 (d, $J = 8.7$ Hz, 2H), 3.76 (s, 3H), 3.65 (t, $J = 4.4$ Hz, 4H), 3.31 (t, $J = 4.7$ Hz, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 155.6, 129.5, 122.5, 114.7, 66.5, 55.6, 47.1. Data is consistent with reported literatures.¹⁻³




N'-(4-hydroxyphenyl)-*N*-diphenylmorpholine-4-carboximidamide (**4sab**) Synthesized according to the General procedure B using 4-aminophenol **2s** (54.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (149.9 mg, 1.0 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4sab** (80.1 mg, 0.27 mmol, 54%) as a brown powder: ¹H NMR (500 MHz, (CD₃)₂SO) δ ppm 7.11 (t, *J* = 7.8 Hz, 2H), 6.82-6.74 (m, 5H), 6.54 (d, *J* = 8.3 Hz, 2H), 3.56 (t, *J* = 4.3 Hz, 4H), 3.20 (t, *J* = 4.2 Hz, 4H). ¹³C NMR (125 MHz, (CD₃)₂SO): δ ppm 151.8, 128.7, 120.2, 115.3, 65.8, 46.8; ¹³C NMR (125 MHz, (CD₃)₂SO + 0.1% TFA): δ ppm 152.8, 151.2, 128.9, 122.0, 121.6, 119.9, 115.5, 65.7, 47.2. Melting point: 192-194°C. ESI-MS: *m/z*: 298.15555 [M+H]⁺ (calcd for [C₁₇H₂₀N₃O₂]⁺ 298.15620).




N'-(4-((*tert*-butyldimethylsilyl)oxy)phenyl)-*N*-phenylmorpholine-4-carboximidamide (**4tab**) Synthesized according to the General procedure B using 4-((*tert*-butyldimethylsilyl)oxy)aniline **2t** (111.7 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4tab** (123.9 mg, 0.3 mmol, 60%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.25 (t, *J* = 7.9 Hz, 2H), 6.99-6.82 (m, 5H), 6.74 (d, *J* = 8.6 Hz, 2H), 3.64 (b, 4H), 3.30 (t, *J* = 4.5 Hz, 4H), 0.96 (s, 9H),

0.16 (s, 6H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 151.5, 129.5, 122.6, 120.9, 66.5, 47.2, 25.8, 18.3, -4.3. ESI-MS: m/z: 412.24336 [M+H]⁺ (calcd for [C₂₃H₃₄N₃O₂Si]⁺ 412.24203).




N-phenyl-*N'*-(pyridin-2-yl)morpholine-4-carboximidamide (**4uab**) Synthesized according to the General procedure A using 1-phenyl-3-(pyridin-2-yl)thioureas **1ua** (114.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **4uab** (71.0 mg, 0.25 mmol, 50%) as a white solid; Synthesized according to the General procedure B using 2-aminopyridine **2u** (47.0 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (149.9 mg, 1.0 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4uab** (11.4 mg, 0.04 mmol, 8%) as a white solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 8.22-8.21 (m, 1H), 7.56-7.53 (m, 1H), 7.28 (t, *J* = 8.0 Hz, 2H), 7.16 (d, *J* = 6.6 Hz, 2H), 7.01-6.98 (m, 2H), 6.82-6.80 (m, 1H), 3.68 (t, *J* = 4.6 Hz, 4H), 3.44 (t, *J* = 4.8 Hz, 4H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 161.7, 154.0, 146.1, 141.1, 137.7, 129.4, 122.9, 121.0, 120.2, 116.8, 66.6, 47.4. Melting point: 86-88°C. Data is consistent with reported literatures.^{1,2}




N'-benzhydryl-*N*-phenylmorpholine-4-carboximidamide (**4vab**) Synthesized according to the General procedure B using benzhydrylamine **2v** (91.6 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide

(149.9 mg, 1.0 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4vab** (88.9 mg, 0.24 mmol, 48%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.32-7.27 (m, 8H), 7.16 (b, 4H), 7.07-7.04 (m, 2H), 6.89-6.86 (m, 1H), 5.63 (s, 1H), 3.74 (t, $J = 4.6$ Hz, 4H), 3.24 (t, $J = 4.7$ Hz, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 129.2, 128.8, 127.5, 127.3, 122.3, 66.9, 62.8, 48.5. Melting point: 142-143°C. ESI-MS: m/z : 372.20858 $[\text{M}+\text{H}]^+$ (calcd for $[\text{C}_{24}\text{H}_{26}\text{N}_3\text{O}]^+$ 372.20759).




Ethyl-3-(((benzhydrylamino)((4-cyanophenyl)amino)methylene)amino)propanoate


(4whv) Synthesized according to the General procedure B using β -alanine ethyl ester hydrochloride **2a** (76.8 mg, 0.5 mmol), phenyl isothiocyanate **3a** (67.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (added twice into the reaction: 1st step: 193.8 mg, 1.5 mmol; 2nd step: 64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4whv** (144.2 mg, 0.34 mmol, 68%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.48-7.46 (m, 2H), 7.35-7.32 (m, 4H), 7.30-7.26 (m, 2H), 7.24-7.23 (m, 4H), 6.92-6.89 (m, 2H), 5.70 (s, 1H), 4.05 (q, $J = 7.1$ Hz, 2H), 3.49 (t, $J = 5.6$ Hz, 2H), 2.50 (t, $J = 5.9$ Hz, 2H), 1.20 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 172.7, 150.4, 141.4, 133.7, 129.1, 128.1, 127.2, 123.9, 120.1, 103.9, 69.1, 60.8, 60.5, 37.3, 34.3, 14.3. ESI-MS: m/z : 427.21480 $[\text{M}+\text{H}]^+$ (calcd for $[\text{C}_{20}\text{H}_{27}\text{N}_4\text{O}_2]^+$ 427.21340).




N-(2-fluorophenyl)-*N'*-phenylmorpholine-4-carboximidamide (**4abb**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), 2-fluorophenyl isothiocyanate **3b** (76.6 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4abb** (116.2 mg, 0.39 mmol, 78%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.26 (m, 2H), 7.01-6.84 (m, 7H), 3.67 (t, *J* = 4.8 Hz, 4H), 3.36 (t, *J* = 4.8 Hz, 4H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 129.4, 124.7 (d, *J* = 3.8 Hz), 123.2, 122.8, 119.2, 118.9, 116.2 (d, *J* = 21.3 Hz), 66.5, 47.2; ¹³C NMR (125 MHz, CD₃OD + 0.1% TFA): δ ppm 155.8, 141.5, 130.1, 126.5, 125.7, 124.6, 121.8, 116.9 (d, *J* = 20.0 Hz), 67.3, 48.9. ESI-MS: *m/z*: 300.15160 [M+H]⁺ (calcd for [C₁₇H₁₉FN₃O]⁺ 300.15122).



N-(4-fluorophenyl)-*N'*-phenylmorpholine-4-carboximidamide (**4acb**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), 4-fluorophenyl isothiocyanate **3c** (76.6 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (149.9 mg, 1.0 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4acb** (70.2 mg, 0.235 mmol, 47%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.28 (m, 2H), 7.01-6.84 (m, 7H), 3.67 (t, *J* = 4.7 Hz, 4H), 3.32 (t, *J* = 4.7 Hz, 4H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 151.3, 129.6, 122.7, 116.2 (d, *J* = 22.5 Hz), 66.5, 47.1; ¹³C NMR (125 MHz, CD₃OD + 0.1% TFA): δ ppm 155.5, 144.2, 138.3, 130.7, 127.2, 125.6, 125.5, 123.4, 117.3 (d, *J* = 23.8 Hz), 66.9, 49.7. ESI-MS: *m/z*: 300.15216 [M+H]⁺ (calcd for [C₁₇H₁₉FN₃O]⁺ 300.15122).




N-(4-chlorophenyl)-*N'*-phenylmorpholine-4-carboximidamide (**4adb**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), 4-chlorophenyl isothiocyanate **3d** (84.8 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4adb** (97.8 mg, 0.31 mmol, 62%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.27 (t, $J = 7.9$ Hz, 2H), 7.19 (d, $J = 8.6$ Hz, 2H), 7.01-6.84 (m, 5H), 3.67 (t, $J = 4.8$ Hz, 4H), 3.32 (t, $J = 4.8$ Hz, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 151.1, 129.6, 129.5, 127.7, 122.8, 66.4, 47.1; ^{13}C NMR (125 MHz, $\text{CD}_3\text{OD} + 0.1\%$ TFA): δ ppm 154.5, 146.5, 145.2, 130.1, 129.8, 128.0, 123.5, 123.3, 121.2, 67.4, 48.4. ESI-MS: m/z : 316.12268 $[\text{M}+\text{H}]^+$ (calcd for $[\text{C}_{17}\text{H}_{19}\text{ClN}_3\text{O}]^+$ 316.12166). Data is consistent with reported literatures³.




N-(4-bromophenyl)-*N'*-phenylmorpholine-4-carboximidamide (**4aeb**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), 4-bromophenyl isothiocyanate **3e** (107.0 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (149.9 mg, 1.0 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aeb** (116.8 mg, 0.325 mmol, 65%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.32 (d, $J = 8.7$ Hz, 2H), 7.26 (t, $J = 7.9$ Hz, 2H), 7.0-6.77 (m, 5H), 3.65 (t, $J = 4.8$ Hz, 4H), 3.31 (t, $J = 4.8$ Hz, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 150.9, 137.9, 132.3, 129.5,

122.7, 115.1, 66.3, 47.0. Melting point: 129-130°C. Data is consistent with reported literatures.¹⁻³




N-(4-iodophenyl)-*N'*-phenylmorpholine-4-carboximidamide (**4afb**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), 4-iodophenyl isothiocyanate **3f** (130.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4afb** (118.2 mg, 0.29 mmol, 58%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.51 (d, *J* = 8.4 Hz, 2H), 7.27-7.24 (m, 2H), 7.0-6.94 (m, 3H), 6.66 (b, 2H), 3.66 (t, *J* = 4.7 Hz, 4H), 3.31 (t, *J* = 4.8 Hz, 4H). ¹³C NMR (125 MHz, CDCl₃): δ ppm 151.0, 138.3, 129.4, 124.9, 122.7, 118.4, 85.5, 66.4, 47.0. Melting point: 148-150°C. Data is consistent with reported literatures.^{1,2}




N'-phenyl-*N*-(4-(trifluoromethyl)phenyl)morpholine-4-carboximidamide (**4agb**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), 4-(trifluoromethyl)phenyl isothiocyanate **3g** (101.6 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (149.9 mg, 1.0 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4agb** (125.6 mg, 0.36 mmol, 72%) as a yellow solid: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.48 (d, *J* = 8.2 Hz, 2H), 7.29-7.26 (overlap with solvent, 2H), 7.02- 6.96 (m, 5H), 3.70 (b, 4H), 3.36 (t, *J* = 4.8 Hz, 4H). ¹³C NMR (125 MHz, CDCl₃): δ ppm

151.2, 143.0, 129.6, 127.8, 126.7 (d, $J = 3.4$ Hz), 125.6, 124.4 (q, $J = 32.2$ Hz, C-F coupling), 123.5, 123.3, 120.0, 66.2, 47.2. ^{19}F NMR (470 MHz, CDCl_3): δ ppm -61.6 ($-\text{CF}_3$). Melting point: 108-109°C. Data is consistent with reported literatures.^{1,2}




N-(4-cyanophenyl)-*N'*-phenylmorpholine-4-carboximidamide (**4ahb**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), 4-cyanophenyl isothiocyanate **3h** (80.1 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4ahb** (125.1 mg, 0.41 mmol, 82%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.47 (d, $J = 8.5$ Hz, 2H), 7.27 (t, $J = 7.9$ Hz, 2H), 7.01 (t, $J = 7.4$ Hz, 1H), 6.93 (d, $J = 7.5$ Hz, 4H), 3.69 (t, $J = 4.7$ Hz, 4H), 3.36 (t, $J = 4.8$ Hz, 4H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 133.6, 129.7, 123.2, 104.8, 66.4, 47.1; ^{13}C NMR (125 MHz, $\text{CD}_3\text{OD} + 0.1\%$ TFA): δ ppm 154.4, 142.0, 134.3, 130.3, 124.9, 122.6, 122.0, 120.1, 106.1, 67.2, 48.9. ESI-MS: m/z : 307.15531 $[\text{M}+\text{H}]^+$ (calcd for $[\text{C}_{18}\text{H}_{19}\text{N}_4\text{O}]^+$ 307.15589).



Ethyl-4-(*N'*-phenylmorpholine-4-carboximidamido)benzoate (**4aib**) Synthesized according to the General procedure B using aniline **2a** (46.6 mg, 0.5 mmol), 4-ethylbenzoate isothiocyanate **3i** (103.5 mg, 0.5 mmol), morpholine **2b** (130.7 mg, 1.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL), to afford **4aib** (134.1 mg, 0.38 mmol, 76%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm

7.92 (d, $J = 8.5$ Hz, 2H), 7.26 (t, $J = 7.8$ Hz, 2H), 7.01-6.92 (m, 5H), 4.32 (q, $J = 7.2$ Hz, 2H), 3.69 (t, $J = 4.7$ Hz, 4H), 3.35 (t, $J = 4.8$ Hz, 4H), 1.36 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 166.6, 131.3, 129.6, 124.2, 123.0, 113.9, 66.4, 60.8, 47.1, 14.5. Melting point: 89-90°C. ESI-MS: m/z : 354.18279 $[\text{M}+\text{H}]^+$ (calcd for $[\text{C}_{20}\text{H}_{24}\text{N}_3\text{O}_3]^+$ 354.18177). Data is consistent with reported literatures.³



Ethyl-*N,N'*-diphenylcarbamiidate (**5ab**) Synthesized according to the General procedure A using 1,3-diphenylthioureas **1aa** (114.0 mg, 0.5 mmol), sodium iodide (74.9 mg, 0.5 mmol), DIPEA (64.6 mg, 0.5 mmol) in ethanol (2.5 mL) and water (2.5 mL) to afford **5ab** (10.4 mg, 0.04 mmol, 8%) as a yellow solid: ^1H NMR (500 MHz, CDCl_3) δ ppm 7.35-7.31 (m, 2H), 7.26 (m, overlap with solvent, 2H), 7.06-6.98 (m, 5H), 4.42 (q, $J = 7.1$ Hz, 2H), 1.43 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3): δ ppm 150.2, 129.8, 129.2, 129.0, 123.1, 122.9, 120.4, 62.9, 14.4, 14.5. ESI-MS: m/z : 241.13421 $[\text{M}+\text{H}]^+$ (calcd for $[\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}]^+$ 241.13409).




Figure S1. Reactors set up.



a)



b)

Figure S2. Electrodes a) Carbon and b) Platinum.




Figure S3. Gram scale set up.




Figure S4 ¹H NMR spectra of 4aab (CDCl₃).




Figure S5 ¹³C NMR spectra of 4aab (CDCl₃).




Figure S6 ¹H NMR spectra of 4aac (CDCl₃).




Figure S7 ¹³C NMR spectra of 4aac (CDCl₃).




Figure S8 ^1H NMR spectra of **4aad** (CDCl_3).




Figure S9 ^{13}C NMR spectra of **4aad** (CDCl_3).




Figure S10 ¹H NMR spectra of 4aae (CDCl₃).




Figure S11 ¹³C NMR spectra of 4aae (CDCl₃).




Figure S12 ^1H NMR spectra of 4aaf (CDCl_3).




Figure S13 ^{13}C NMR spectra of 4aaf (CDCl_3).




Figure S14 ¹H NMR spectra of 4aag (CDCl₃).




Figure S15 ¹³C NMR spectra of 4aag (CDCl₃).




Figure S16 ¹H NMR spectra of 4aah (CDCl₃).




Figure S17 ¹³C NMR spectra of 4aah (CDCl₃).




Figure S18 ^1H NMR spectra of **4aaa** (CDCl₃).




Figure S19 ^{13}C NMR spectra of **4aaa** (CDCl₃).




Figure S20 ¹³C NMR spectra of 4aaa (CD₃OD + 0.1% TFA).




Figure S21 ¹H NMR spectra of 4aai (CDCl₃).




Figure S22 ^{13}C NMR spectra of 4aai (CDCl_3).




Figure S23 ^1H NMR spectra of 4aal (CDCl_3).




Figure S24 ^{13}C NMR spectra of 4aal (CDCl_3).




Figure S25 ^1H NMR spectra of 4aam (CDCl_3).




Figure S26 ¹³C NMR spectra of 4aam (CDCl₃).




Figure S27 ¹H NMR spectra of 4aam (CDCl₃).




Figure S28 ¹³C NMR spectra of 4aan (CDCl₃)




Figure S29 ¹H NMR spectra of 4aao (CDCl₃).




Figure S30 ¹³C NMR spectra of 4aao (CDCl₃).




Figure S31 ¹H NMR spectra of 4aap (CDCl₃).




Figure S32 ¹³C NMR spectra of 4aap (CDCl₃).




Figure S33 ¹H NMR spectra of 4qab (CDCl₃).




Figure S34 ¹³C NMR spectra of 4qab (CDCl₃).




Figure S35 ¹H NMR spectra of 4rab (CDCl₃).




Figure S36 ¹³C NMR spectra of **4rab** (CDCl₃).




Figure S37 ¹H NMR spectra of **4iab** (CDCl₃).




Figure S38 ¹³C NMR spectra of **4iab** (CDCl₃).




Figure S39 ¹H NMR spectra of **4sab** ((CD₃)₂SO).




Figure S40 ^{13}C NMR spectra of 4sab ($(\text{CD}_3)_2\text{SO}$).




Figure S41 ^{13}C NMR spectra of 4sab ($(\text{CD}_3)_2\text{SO} + 0.1\%$ TFA).




Figure S42 ^1H NMR spectra of **4tab** (CDCl₃).




Figure S43 ^{13}C NMR spectra of **4tab** (CDCl₃).




Figure S44 ^1H NMR spectra of 4uab (CDCl_3).




Figure S45 ^{13}C NMR spectra of 4uab (CDCl_3).




Figure S46 ^1H NMR spectra of 4vab (CDCl_3).






Figure S47 ^{13}C NMR spectra of 4vab (CDCl_3).






Figure S50 ¹H NMR spectra of 4abb (CDCl₃).




Figure S51 ¹³C NMR spectra of 4abb (CDCl₃).




Figure S52 ¹³C NMR spectra of **4abb** (CD₃OD + 0.1% TFA).




Figure S53 ¹H NMR spectra of **4acb** (CDCl₃).




Figure S54 ^{13}C NMR spectra of **4acb** (CDCl_3).




Figure S55 ^{13}C NMR spectra of **4acb** ($\text{CD}_3\text{OD} + 0.1\% \text{TFA}$).




Figure S56 ^1H NMR spectra of 4adb (CDCl_3).




Figure S57 ^{13}C NMR spectra of 4adb (CDCl_3).




Figure S58 ¹³C NMR spectra of 4aag (CD₃OD + 0.1% TFA).




Figure S59 ¹H NMR spectra of 4aeb (CDCl₃).




Figure S60 ¹³C NMR spectra of 4aeb (CDCl₃).




Figure S61 ¹H NMR spectra of 4afb (CDCl₃).




Figure S62 ^{13}C NMR spectra of **4afb** (CDCl_3).




Figure S63 ^1H NMR spectra of **4agb** (CDCl_3).




Figure S64 ^{13}C NMR spectra of 4agb (CDCl_3).




Figure S65 ^{19}F NMR spectra of 4agb (CDCl_3).




Figure S66 ^1H NMR spectra of 4ahb (CDCl_3).




Figure S67 ^{13}C NMR spectra of 4ahb (CDCl_3).




Figure S68 ¹³C NMR spectra of 4ahb (CD₃OD + 0.1% TFA).




Figure S69 ¹H NMR spectra of 4aib (CDCl₃).




Figure S70 ^{13}C NMR spectra of **4aib** (CDCl_3).




Figure S71 ^1H NMR spectra of **5ab** (CDCl_3).




Figure S72 ^{13}C NMR spectra of **5ab** (CDCl_3).

Generic Display Report

Analysis Info

Analysis Name	D:\Data\Data Service\230515\TM_FbNH2 Guanidine_RA8_01_7106.d	Acquisition Date	5/15/2023 1:44:15 PM
Method	nv_pos_5min_profile_190214.m	Operator	CU.
Sample Name	TM_FbNH2 Guanidine	Instrument	micrOTOF-Q
Comment			





Figure S73 Mass spectrum of 4aag.

Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\230515\TM_PhNH2 Model Guanidine_RB1_01_7107.d
Method nv_pos_5min_profile_190214.m
Sample Name TM_PhNH2 Model Guanidine
Comment

Acquisition Date 5/15/2023 1:50:42 PM

Operator CU.

Instrument micrOTOF-Q





Figure S74 Mass spectrum of 4aaa.

Generic Display Report

Analysis Info

Analysis Name	D:\Data\Data Service\230612\TM_4-OH Guanidine_RA6_01_7179.d	Acquisition Date	6/12/2023 3:25:24 PM
Method	nv_pos_5min_profile_190214.m	Operator	CU.
Sample Name	TM_4-OH Guanidine	Instrument	micrOTOF-Q
Comment			





Figure S75 Mass spectrum of 4sab.

Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\230612\TM_4-OTBDMS Guanidine_RB1_01_7172.d
Method nv_pos_5min_profile_190214.m
Sample Name TM_4-OTBDMS Guanidine
Comment

Acquisition Date 6/12/2023 2:41:00 PM
Operator CU.
Instrument micrOTOF-Q





Figure S76 Mass spectrum of 4tab.

Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\230612\TM_PH2CHNH2 Guanidine_RA5_01_7178.d
Method nv_pos_5min_profile_190214.m
Sample Name TM_PH2CHNH2 Guanidine
Comment

Acquisition Date 6/12/2023 3:19:07 PM
Operator CU.
Instrument micrOTOF-Q





Figure S77 Mass spectrum of 4vab.

Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\230612\TM_SW Guanidine_RA4_01_7175.d
Method nv_pos_5min_profile_190214.m
Sample Name TM_SW Guanidine
Comment

Acquisition Date 6/12/2023 3:00:04 PM
Operator CU.
Instrument micrOTOF-Q





Figure S78 Mass spectrum of 4whv.

Generic Display Report

Analysis Info

Analysis Name	D:\Data\Data Service\230515\TM_2-FGuanidine_RA7_01_7105.d	Acquisition Date	5/15/2023 1:37:48 PM
Method	nv_pos_5min_profile_190214.m	Operator	CU.
Sample Name	TM_2-FGuanidine	Instrument	micrOTOF-Q
Comment			





Figure S79 Mass spectrum of 4abb.

Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\230515\TM_4-FGuanidine_RA6_01_7104.d
Method nv_pos_5min_profile_190214.m
Sample Name TM_4-FGuanidine
Comment

Acquisition Date 5/15/2023 1:31:20 PM
Operator CU.
Instrument micrOTOF-Q





Figure S80 Mass spectrum of 4acb.

Generic Display Report

Analysis Info

Analysis Name	D:\Data\Data Service\230612\TM_4-Cl Guanidine_RA7_01_7170.d	Acquisition Date	6/12/2023 2:28:25 PM
Method	nv_pos_5min_profile_190214.m	Operator	CU.
Sample Name	TM_4-Cl Guanidine	Instrument	micrOTOF-Q
Comment			





Figure S81 Mass spectrum of 4adb.

Generic Display Report

Analysis Info

Analysis Name	D:\Data\Data Service\230515\TM_4-CNGuanidine_RA5_01_7103.d	Acquisition Date	5/15/2023 1:24:54 PM
Method	nv_pos_5min_profile_190214.m	Operator	CU.
Sample Name	TM_4-CNGuanidine	Instrument	micrOTOF-Q
Comment			





Figure S82 Mass spectrum of 4ahb.

Generic Display Report

Analysis Info

Analysis Name	D:\Data\Data Service\230612\TM_4-CO2Et Guanidine_RA8_01_7171.d	Acquisition Date	6/12/2023 2:34:42 PM
Method	nv_pos_5min_profile_190214.m	Operator	CU.
Sample Name	TM_4-CO2Et Guanidine	Instrument	micrOTOF-Q
Comment			





Figure S83 Mass spectrum of 4aib.

Generic Display Report

Analysis Info

Analysis Name D:\Data\Data Service\230807\TM_EtOH Guanidine_RC6_01_7439.d
Method nv_pos_5min_profile_190214.m
Sample Name TM_EtOH Guanidine
Comment

Acquisition Date 8/7/2023 4:48:26 PM

Operator CU.
Instrument micrOTOF-Q





Figure S84 Mass spectrum of **5ab**.





Figure S85 Mass spectrum of compound **5ab** from GC-MS.



Scheme S2. Cyclic voltammogram of **1aa**, **2b** and **NaI** in 0.1 M TBABF₄/EtOH:H₂O (1:1) using glassy carbon electrode ($A = 0.71 \text{ cm}^2$) as working electrode, Pt wire and Ag/AgCl (3M KCl) as counter and reference electrodes at scan rate 0.1 V/s. In case of **1aa**, **2b**, NaI, **1aa/2b**, and **1aa/2b/NaI** experiments, 10 mM solution of compounds were prepared.

References

1. Saetan, T.; Sukwattanasinitt, M.; Wacharasindhu, S., A mild photocatalytic synthesis of guanidine from thiourea under visible light. *Org. Lett.* **2020**, *22*, 7864-7869.
2. Annuur, R. M.; Saetan, T.; Sukwattanasinitt, M.; Wacharasindhu, S., Metal-free synthesis of guanidines from thioureas in water reactions mediated by visible light. *Synthesis* **2023**.
3. Wan, Y.; Wu, H.; Ma, N.; Zhao, J.; Zhang, Z.; Gao, W.; Zhang, G., *De novo* design and synthesis of dipyrrolopyridone derivatives as visible-light photocatalysts in productive guanylation reactions. *Chem. Sci.* **2021**, *12*, 15988-15997.